Johnson & Johnson Price to Free Cash Flow Ratio 2010-2024 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-11-01 |
160.13 |
|
18.42 |
| 2024-09-30 |
162.06 |
$8.69 |
18.64 |
| 2024-06-30 |
145.06 |
$8.48 |
17.10 |
| 2024-03-31 |
155.72 |
$7.59 |
20.51 |
| 2023-12-31 |
153.13 |
$7.27 |
21.07 |
| 2023-09-30 |
150.96 |
$6.28 |
24.04 |
| 2023-06-30 |
159.29 |
$5.63 |
28.32 |
| 2023-03-31 |
148.04 |
$6.23 |
23.76 |
| 2022-12-31 |
167.54 |
$6.65 |
25.18 |
| 2022-09-30 |
153.95 |
$6.80 |
22.65 |
| 2022-06-30 |
166.16 |
$7.60 |
21.85 |
| 2022-03-31 |
164.86 |
$7.52 |
21.94 |
| 2021-12-31 |
158.11 |
$7.65 |
20.65 |
| 2021-09-30 |
148.28 |
$8.72 |
17.00 |
| 2021-06-30 |
150.36 |
$8.77 |
17.14 |
| 2021-03-31 |
149.07 |
$8.14 |
18.31 |
| 2020-12-31 |
141.87 |
$7.67 |
18.49 |
| 2020-09-30 |
133.27 |
$6.91 |
19.29 |
| 2020-06-30 |
125.05 |
$6.65 |
18.81 |
| 2020-03-31 |
115.80 |
$8.50 |
13.62 |
| 2019-12-31 |
127.98 |
$8.64 |
14.82 |
| 2019-09-30 |
112.73 |
$9.35 |
12.06 |
| 2019-06-30 |
121.36 |
$8.74 |
13.88 |
| 2019-03-31 |
120.97 |
$8.04 |
15.04 |
| 2018-12-31 |
110.95 |
$7.97 |
13.93 |
| 2018-09-30 |
118.03 |
$7.48 |
15.79 |
| 2018-06-30 |
102.97 |
$7.70 |
13.37 |
| 2018-03-31 |
107.95 |
$7.36 |
14.66 |
| 2017-12-31 |
116.95 |
$7.14 |
16.37 |
| 2017-09-30 |
108.17 |
$7.11 |
15.21 |
| 2017-06-30 |
109.37 |
$6.62 |
16.51 |
| 2017-03-31 |
102.29 |
$6.33 |
16.16 |
| 2016-12-31 |
94.01 |
$6.03 |
15.60 |
| 2016-09-30 |
95.73 |
$5.86 |
16.32 |
| 2016-06-30 |
97.65 |
$6.19 |
15.77 |
| 2016-03-31 |
86.49 |
$6.66 |
12.99 |
| 2015-12-31 |
81.52 |
$6.96 |
11.72 |
| 2015-09-30 |
73.54 |
$6.13 |
12.00 |
| 2015-06-30 |
76.18 |
$6.80 |
11.20 |
| 2015-03-31 |
78.07 |
$6.56 |
11.90 |
| 2014-12-31 |
80.59 |
$6.85 |
11.76 |
| 2014-09-30 |
81.61 |
$6.76 |
12.08 |
| 2014-06-30 |
79.56 |
$5.83 |
13.66 |
| 2014-03-31 |
74.19 |
$5.49 |
13.51 |
| 2013-12-31 |
68.68 |
$4.96 |
13.84 |
| 2013-09-30 |
64.56 |
$4.94 |
13.08 |
| 2013-06-30 |
63.47 |
$4.71 |
13.47 |
| 2013-03-31 |
59.81 |
$4.64 |
12.89 |
| 2012-12-31 |
51.02 |
$4.97 |
10.27 |
| 2012-09-30 |
49.72 |
$5.02 |
9.91 |
| 2012-06-30 |
48.31 |
$5.05 |
9.56 |
| 2012-03-31 |
46.71 |
$4.83 |
9.68 |
| 2011-12-31 |
46.04 |
$4.59 |
10.02 |
| 2011-09-30 |
44.30 |
$4.62 |
9.58 |
| 2011-06-30 |
45.86 |
$4.71 |
9.74 |
| 2011-03-31 |
40.49 |
$4.72 |
8.59 |
| 2010-12-31 |
41.89 |
$5.21 |
8.04 |
| 2010-09-30 |
41.61 |
$5.76 |
7.22 |
| 2010-06-30 |
39.29 |
$5.69 |
6.91 |
| 2010-03-31 |
42.98 |
$5.50 |
7.81 |
| 2009-12-31 |
42.14 |
$5.15 |
8.18 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$385.533B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
